Handok (002390) - Total Liabilities

Latest as of March 2026: ₩530.85 Billion KRW ≈ $359.75 Million USD

Based on the latest financial reports, Handok (002390) has total liabilities worth ₩530.85 Billion KRW (≈ $359.75 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Handok long-term investment allocation to see how much of total assets are deployed in long-term investments.

Handok - Total Liabilities Trend (2011–2025)

This chart illustrates how Handok's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of Handok.

Handok Competitors by Total Liabilities

The table below lists competitors of Handok ranked by their total liabilities.

Company Country Total Liabilities
Tan Chong Motor Holdings Bhd
KLSE:4405
Malaysia RM2.21 Billion
Hotron Precision Electronic Industrial Co Ltd
TW:3092
Taiwan NT$3.62 Billion
EN Shoham Business Ltd
TA:SHOM
Israel ILA861.73 Million
Kapsch Traffic
VI:KTCG
Austria €322.77 Million
Kpx Green Chem
KO:083420
Korea ₩80.47 Billion
Fintech Ecosystem Development Corp
NASDAQ:FEXD
USA $7.89 Million
SSF Home Group Berhad
KLSE:0287
Malaysia RM104.38 Million
kenturn Nano Tec Co Ltd
TWO:4561
Taiwan NT$859.47 Million

Liability Composition Analysis (2011–2025)

This chart breaks down Handok's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Handok net asset quality index to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.77 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.99 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.66 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Handok's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Handok (2011–2025)

The table below shows the annual total liabilities of Handok from 2011 to 2025.

Year Total Liabilities Change
2025-12-31 ₩512.43 Billion
≈ $347.27 Million
+2.59%
2024-12-31 ₩499.49 Billion
≈ $338.50 Million
+11.07%
2023-12-31 ₩449.71 Billion
≈ $304.76 Million
-8.08%
2022-12-31 ₩489.25 Billion
≈ $331.56 Million
+6.92%
2021-12-31 ₩457.57 Billion
≈ $310.09 Million
+4.69%
2020-12-31 ₩437.08 Billion
≈ $296.20 Million
+8.01%
2019-12-31 ₩404.67 Billion
≈ $274.24 Million
+19.29%
2018-12-31 ₩339.24 Billion
≈ $229.90 Million
-2.69%
2017-12-31 ₩348.63 Billion
≈ $236.26 Million
+4.51%
2016-12-31 ₩333.60 Billion
≈ $226.08 Million
+47.04%
2015-12-31 ₩226.88 Billion
≈ $153.75 Million
+9.23%
2014-12-31 ₩207.71 Billion
≈ $140.76 Million
+15.88%
2013-12-31 ₩179.25 Billion
≈ $121.48 Million
+20.19%
2012-12-31 ₩149.14 Billion
≈ $101.07 Million
+14.83%
2011-12-31 ₩129.88 Billion
≈ $88.02 Million
--

About Handok

KO:002390 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$74.39 Million
₩109.77 Billion KRW
Market Cap Rank
#20450 Global
#1118 in Korea
Share Price
₩8450.00
Change (1 day)
-4.95%
52-Week Range
₩6700.00 - ₩12070.00
All Time High
₩38942.94
About

HANDOK Inc. operates as a pharmaceutical company. The company provides prescription and OTC drugs; medical devices, such as blood pressure monitors, cholesterol monitoring systems, insulin pumps, self-monitoring system of blood glucose, and blood glucose monitoring system; in vitro diagnostic medical devices; as well as life science products. It also offers healthcare products comprising food sup… Read more